top of page
CRISPR SARS-CoV-2 kit is
the first FDA-authorized
* The fastest, highest sensitivity and specificity Covid Test in the world
* Highest detection rate for Omicron variant
* The first CRISPR Covid Test with CE mark to supply worldwide
** If you are interested in becoming our distributor and selling our product in your territories/country, please fill in the form below and specify your area of interest **
Together we will improve health outcomes worldwide.
CRISPR-based detection methods have received substantial attention for nucleic acid-based molecular testing due to their simplicity, high sensitivity, and specificity. This is essential to ending the pandemic now, and to strengthening global health security for tomorrow—to better prevent, detect, and respond to the next threat. That’s why we are partnering with leading organizations to develop and commercialize tests using Engineering Biology technologies. We work alongside partners to rapidly develop better tests and put them in the hands of more people.
Global CRISPR Technology Market Research Report 2021
The global CRISPR technology market is expected to grow from $0.8 billion in 2020 to $0.95 billion in 2021 at a compound annual growth rate (CAGR) of 18.8%. The market is expected to reach $2.22 billion in 2025 at a CAGR of 24%
CRISPR in a diagnostic has huge potential for at-home COVID-19 testing and beyond.
CRISPR startup Sherlock Biosciences was in the middle of working on CRISPR-based tests that could deliver lab-quality testing at home for common illnesses like flu or sexually transmitted infections like chlamydia or gonorrhea. When COVID-19 struck, the company quickly got to work on a lab test for it.
Sherlock Biosciences’ 221b Foundation Enables Global Access to COVID-19 Diagnostics with Up To 10 Million Tests Per Month.
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that its partnerships will increase COVID-19 diagnostic manufacturing capacity by up to 10 million tests per month by year-end. Through multiple license agreements this year with organizations including ALBOT Technologies, Cooper International, LogicInk, Rokline, United PPE, and binx health.
News & Article
In Silico Analysis – Summary Report
A bioinformatic analysis was carried out to determine the in silico inclusivity of all SHERLOCK-kit molecular components against all recent (including Omicron) Sars CoV-2 genomes
Request a copy
bottom of page